Trial Profile
Open Label Phase 1 Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 May 2010
Price :
$35
*
At a glance
- Drugs TRC 102 (Primary) ; Pemetrexed
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors TRACON Pharmaceuticals
- 20 May 2010 Final results will be presented at ASCO 2010, according to a TRACON media release.
- 10 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Feb 2010 Planned end date changed from 1 Feb 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.